Esketamine is the first non-monoaminergic based medication which is FDA approved and indicated for treatment refractory depression. A longer duration of undertreated depression is associated with poor longitudinal functional outcomes. Instead of cycling patients through monoaminergic antidepressant trials and cognitive behavioral therapy approaches, according to Dr. Kitay, providers should consider treatments like esketamine much sooner in the treatment course.
Link to full blog
More Episodes
The Fentanyl Epidemic
2019-11-14
2019-11-14
Is Social Media Good for Mental Health?
2019-11-07
2019-11-07
Interviewing Well For Residency & Beyond
2019-10-16
2019-10-16
Therapeutic Alliance Part 5: Emotion
2019-10-03
2019-10-03
Which Foods are Good for Mental Health?
2019-09-12
2019-09-12
How To Pick A Good Therapist
2019-08-10
2019-08-10
The Process of Grief
2019-07-04
2019-07-04
Schizophrenia Differential Diagnosis & DSM5
2019-06-06
2019-06-06
Get this podcast on your
phone, FREE
